HUE055682T2 - Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések - Google Patents

Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések

Info

Publication number
HUE055682T2
HUE055682T2 HUE13186454A HUE13186454A HUE055682T2 HU E055682 T2 HUE055682 T2 HU E055682T2 HU E13186454 A HUE13186454 A HU E13186454A HU E13186454 A HUE13186454 A HU E13186454A HU E055682 T2 HUE055682 T2 HU E055682T2
Authority
HU
Hungary
Prior art keywords
stabilize
formulations
immunogenic compositions
inhibit precipitation
precipitation
Prior art date
Application number
HUE13186454A
Other languages
English (en)
Inventor
Lakshmi Khandke
Hanyoung Han
Robert Chancey Seid Jr
Zhaowei Jin
Jee Loon Look
Ronald Malone
Xudong Yang
Ying Chen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38441477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE055682(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of HUE055682T2 publication Critical patent/HUE055682T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE13186454A 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések HUE055682T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79526106P 2006-04-26 2006-04-26

Publications (1)

Publication Number Publication Date
HUE055682T2 true HUE055682T2 (hu) 2021-12-28

Family

ID=38441477

Family Applications (5)

Application Number Title Priority Date Filing Date
HUE13185292A HUE042923T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUE13186453A HUE058394T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUE13186454A HUE055682T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUE07760907A HUE028137T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUS2200028C HUS2200028I1 (hu) 2006-04-26 2022-06-09 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HUE13185292A HUE042923T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUE13186453A HUE058394T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE07760907A HUE028137T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUS2200028C HUS2200028I1 (hu) 2006-04-26 2022-06-09 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések

Country Status (30)

Country Link
US (3) US7935787B2 (hu)
EP (5) EP2676679B2 (hu)
JP (7) JP5612305B2 (hu)
KR (9) KR20210111326A (hu)
CN (4) CN105879021B (hu)
AR (2) AR060665A1 (hu)
AU (1) AU2007243019B2 (hu)
BR (2) BR122020000285B1 (hu)
CA (3) CA2803111C (hu)
CL (1) CL2007001185A1 (hu)
CR (1) CR10405A (hu)
CY (2) CY1116966T1 (hu)
DK (4) DK2679244T3 (hu)
EA (2) EA017436B1 (hu)
ES (4) ES2910432T3 (hu)
FR (1) FR22C1027I1 (hu)
HK (3) HK1196546A1 (hu)
HR (3) HRP20151203T1 (hu)
HU (5) HUE042923T2 (hu)
IL (3) IL194753A (hu)
LT (2) LT2676679T (hu)
MX (3) MX359741B (hu)
PL (4) PL2010219T3 (hu)
PT (4) PT2679244T (hu)
RU (1) RU2482878C2 (hu)
SI (4) SI2679244T1 (hu)
TR (1) TR201902402T4 (hu)
TW (1) TW200806315A (hu)
WO (1) WO2007127665A2 (hu)
ZA (1) ZA200809167B (hu)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944371B1 (en) 1998-05-01 2015-03-04 Novartis AG Neisseria meningitidis antigens and compositions
DK2270173T3 (en) 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
ES2564463T3 (es) 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Péptidos antigénicos de Neisseriales
CN100339482C (zh) 2000-02-28 2007-09-26 启龙股份公司 奈瑟球菌蛋白质的杂交表达
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
BRPI0822098A2 (pt) * 2007-12-21 2015-06-30 Glaxosmithkline Biolog Sa Componente para uma vacina contra malária, vacina para malária, processo para a preparação do componente, uso do componente, e, método de tratar um paciente suscetível às infecções por plasmodium
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
CA2756533A1 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
SI2575870T1 (sl) * 2010-06-04 2017-01-31 Wyeth Llc Formulacije cepiva
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
FR2966044B1 (fr) * 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
HUE029457T2 (hu) 2010-11-11 2017-02-28 Abbvie Biotechnology Ltd Folyékony készítmények, amelyek nagy koncentrációban tartalmaznak ANTI-TNF-alfa antitestet
WO2012078482A1 (en) * 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
CA2862247A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX351993B (es) 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
CA2876138C (en) 2012-06-14 2023-09-19 Novartis Ag Vaccines for serogroup x meningococcus
CN104509112B (zh) 2012-06-26 2018-08-31 Lg 电子株式会社 视频解码方法和使用其的装置
JOP20200175A1 (ar) * 2012-07-03 2017-06-16 Novartis Ag حقنة
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
WO2015033251A2 (en) 2013-09-08 2015-03-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SI3060256T1 (sl) * 2013-10-25 2019-08-30 Bayer Pharma Aktiengesellschaft Nova stabilna formulacija
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN114887048A (zh) * 2014-01-21 2022-08-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10729780B2 (en) * 2015-06-08 2020-08-04 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
RU2721128C2 (ru) * 2015-07-21 2020-05-18 Пфайзер Инк. Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения
US10702606B2 (en) * 2015-12-10 2020-07-07 Menicon Co., Ltd. Peptide composition
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
CA3048981A1 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN106620681A (zh) * 2017-01-12 2017-05-10 南京佰泰克生物技术有限公司 一种细胞裂解液、试剂盒及在制备肿瘤全细胞抗原负载dc肿瘤疫苗中的应用
KR20220011796A (ko) 2017-01-31 2022-01-28 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
WO2018144438A1 (en) * 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
KR20190108583A (ko) 2017-01-31 2019-09-24 머크 샤프 앤드 돔 코포레이션 다당류-단백질 접합체 제조 방법
EP3585427A4 (en) * 2017-02-24 2020-12-30 Merck Sharp & Dohme Corp. METHODS FOR IMPROVING THE FILTRABILITY OF POLYSACCHARIDE CONJUGATE WITH PROTEIN REACTIONS
EP3589314A4 (en) 2017-02-24 2021-04-21 Merck Sharp & Dohme Corp. INCREASED IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE PROTEIN CONJUGATES
US20200054740A1 (en) * 2017-02-24 2020-02-20 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
BR112020004471A8 (pt) 2017-09-07 2022-11-01 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
WO2019083865A1 (en) * 2017-10-25 2019-05-02 Merck Sharp & Dohme Corp. VACCINES WITH ADJUVANT
MA51049A (fr) 2017-12-06 2020-10-14 Merck Sharp & Dohme Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
KR20210005158A (ko) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2019346403A1 (en) * 2018-09-24 2021-04-29 BioVaxys Inc. Bihaptenized autologous vaccines and uses thereof
GEP20247633B (en) 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
EP4297776A1 (en) 2021-02-26 2024-01-03 Biological E Limited Activated-quenched polysaccharide and improved methods for quantification of polysaccharide in a vaccine composition

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1189340A (en) * 1967-09-13 1970-04-22 American Cyanamid Co Antigen-Adjuvant Composition
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
ATE129906T1 (de) 1990-07-19 1995-11-15 Nardino Righi Sicherheitsspritze zum einmaligen gebrauch.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5769047A (en) 1991-12-23 1998-06-23 Zoche; Michael Engine with oil separator
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
SG90042A1 (en) 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3696267B2 (ja) 1994-02-28 2005-09-14 天野エンザイム株式会社 生理活性蛋白質の安定化方法
DE4407489A1 (de) * 1994-03-07 1995-09-14 Bayer Ag Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
RU2098109C1 (ru) * 1996-09-26 1997-12-10 Александр Григорьевич Чучалин Противоаллергическое, противовоспалительное средство, способ его получения, лечебное и косметическое средства с его использованием
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
JP4078406B2 (ja) 1997-01-22 2008-04-23 有限会社コーキ・エンジニアリング 注射器のシリンダの製造方法
CN1259051A (zh) * 1997-04-08 2000-07-05 麦克公司 稳定化后的人乳头瘤病毒制剂
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
CA2264970A1 (en) * 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
KR100659803B1 (ko) 1998-09-30 2006-12-19 와이어쓰 홀딩스 코포레이션 보조제로서 돌연변이체 콜레라 홀로톡신
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
EP1163000B1 (en) 1999-03-19 2008-02-27 GlaxoSmithKline Biologicals S.A. Vaccine against antigens from bacteriae
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
WO2001041800A2 (en) * 1999-12-02 2001-06-14 Chiron Corporation Compositions and methods for stabilizing biological molecules upon lyophilization
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
MXPA02012010A (es) 2000-06-08 2005-04-22 Intercell Biomedizinishce Fors Oligodesoxinucleotidos inmunoestimulantes.
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
HU227613B1 (en) * 2000-06-29 2011-09-28 Glaxosmithkline Biolog Sa Vaccine composition
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
WO2002004497A2 (en) * 2000-07-10 2002-01-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multiple antigenic peptides immunogenic against streptococcus pneumoniae
GB0025414D0 (en) * 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
JP2004525921A (ja) * 2001-03-19 2004-08-26 イオマイ コーポレイシヨン 経皮免疫用パッチ
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
KR100898648B1 (ko) 2001-06-07 2009-05-22 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
RU2323002C2 (ru) * 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
EP1590459A2 (en) 2003-01-15 2005-11-02 Wyeth Holdings Corporation Methods for increasing neisseria protein expression and compositions thereof
CN102302776B (zh) * 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
EP2236154B1 (en) * 2003-02-10 2018-05-30 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
JP2006525330A (ja) 2003-04-16 2006-11-09 ワイエス・ホールディングス・コーポレーション 髄膜炎菌性疾患の予防および処置のための新規免疫原性組成物
CA2529873A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
UA67144A (en) 2003-07-29 2004-06-15 Inst Exprm & Clinical Veterina Method for production of inactivated vaccine against salmonellosis and escherichiosis of animals
EP1651262A2 (en) 2003-08-06 2006-05-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Process for preparing polysaccharide-protein conjugate vaccines
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
RU37462U1 (ru) 2004-01-16 2004-04-27 Бычкова Ольга Владимировна Пробирка
US7858101B2 (en) * 2004-11-01 2010-12-28 The Brigham And Women's Hospital, Inc. Modified streptococcal polysaccharides and uses thereof
AU2006207901A1 (en) * 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102564388B1 (ko) * 2005-04-08 2023-08-08 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
CA2716399C (en) 2008-03-05 2020-07-21 Pierre Chouvenc Process for stabilizing an adjuvant containing vaccine composition

Also Published As

Publication number Publication date
PL2010219T3 (pl) 2016-03-31
EP2679245B1 (en) 2021-07-28
SI2676679T1 (sl) 2019-03-29
AR060665A1 (es) 2008-07-02
BRPI0710918A2 (pt) 2012-03-06
HUS2200028I1 (hu) 2022-07-28
HRP20190198T1 (hr) 2019-04-05
ES2885762T3 (es) 2021-12-15
EA200870480A1 (ru) 2009-04-28
AU2007243019B2 (en) 2012-06-21
EA017436B1 (ru) 2012-12-28
CN105879021B (zh) 2020-11-24
JP2009535353A (ja) 2009-10-01
EA201200929A1 (ru) 2013-05-30
EP2679244A2 (en) 2014-01-01
TW200806315A (en) 2008-02-01
MX2018012171A (es) 2021-12-08
CA2803111C (en) 2015-06-16
KR20220061256A (ko) 2022-05-12
HUE042923T2 (hu) 2019-07-29
DK2676679T3 (en) 2019-03-04
JP2019194240A (ja) 2019-11-07
PT2010219E (pt) 2016-01-29
SI2679244T1 (sl) 2022-05-31
US20110172393A1 (en) 2011-07-14
US20130034580A1 (en) 2013-02-07
PL2676679T3 (pl) 2019-06-28
ES2910432T3 (es) 2022-05-12
CN103768615A (zh) 2014-05-07
WO2007127665A3 (en) 2008-11-13
EP3517129A1 (en) 2019-07-31
HK1209358A1 (en) 2016-04-01
PL2679244T3 (pl) 2022-06-20
HRP20211417T1 (hr) 2021-12-10
MX359741B (es) 2018-10-09
KR20170122857A (ko) 2017-11-06
CN103768615B (zh) 2016-06-01
KR101514847B1 (ko) 2015-04-24
PT2679244T (pt) 2022-04-19
JP2014055169A (ja) 2014-03-27
IL239978A0 (en) 2015-08-31
EP2679245A3 (en) 2014-01-15
CA2650056C (en) 2013-07-16
US20070253984A1 (en) 2007-11-01
IL194753A0 (en) 2009-08-03
BRPI0710918B1 (pt) 2021-02-02
CA2803111A1 (en) 2007-11-08
PT2676679T (pt) 2019-03-01
EP2676679B1 (en) 2019-01-02
KR20210111326A (ko) 2021-09-10
JP6321094B2 (ja) 2018-05-09
KR101514913B1 (ko) 2015-04-23
EP2010219B1 (en) 2015-10-28
KR102093269B1 (ko) 2020-04-23
CA2873346C (en) 2017-09-05
SI2010219T1 (sl) 2015-12-31
HK1223569A1 (zh) 2017-08-04
EP2676679A2 (en) 2013-12-25
AR110731A2 (es) 2019-04-24
CA2873346A1 (en) 2007-11-08
CN104857524B (zh) 2018-08-28
IL239978B (en) 2019-06-30
CN105879021A (zh) 2016-08-24
PT2679245T (pt) 2021-09-02
EP2676679A3 (en) 2014-01-01
KR20160049063A (ko) 2016-05-04
HUE058394T2 (hu) 2022-08-28
HK1196546A1 (zh) 2014-12-19
IL194753A (en) 2015-08-31
IL239788A0 (en) 2015-08-31
CN101500612B (zh) 2013-12-25
EP2676679B2 (en) 2024-08-28
ES2557504T3 (es) 2016-01-26
CN101500612A (zh) 2009-08-05
MX2008013572A (es) 2009-03-06
CY1121251T1 (el) 2020-05-29
JP6192115B2 (ja) 2017-09-06
JP5612305B2 (ja) 2014-10-22
LT2676679T (lt) 2019-03-12
PL2679245T3 (pl) 2021-11-08
KR20140004258A (ko) 2014-01-10
JP2021176910A (ja) 2021-11-11
EP2679244B1 (en) 2022-03-23
AU2007243019A1 (en) 2007-11-08
CN104857524A (zh) 2015-08-26
CY1116966T1 (el) 2017-04-05
SI2679245T1 (sl) 2021-11-30
WO2007127665A2 (en) 2007-11-08
BR122020000285B1 (pt) 2023-05-09
JP2018123145A (ja) 2018-08-09
CR10405A (es) 2009-02-26
EP2679244A3 (en) 2014-01-15
BRPI0710918B8 (pt) 2021-05-25
US8562999B2 (en) 2013-10-22
ES2712956T3 (es) 2019-05-16
CA2650056A1 (en) 2007-11-08
US7935787B2 (en) 2011-05-03
EA023470B1 (ru) 2016-06-30
KR20200032268A (ko) 2020-03-25
DK2679244T3 (da) 2022-04-11
KR20180130004A (ko) 2018-12-05
DK2679245T3 (da) 2021-09-06
RU2008141680A (ru) 2010-06-10
CL2007001185A1 (es) 2008-01-18
JP2014221806A (ja) 2014-11-27
EP2010219A2 (en) 2009-01-07
KR20140132779A (ko) 2014-11-18
HRP20151203T1 (hr) 2015-12-04
KR20090017537A (ko) 2009-02-18
FR22C1027I1 (fr) 2022-09-09
TR201902402T4 (tr) 2019-03-21
ZA200809167B (en) 2009-06-24
HUE028137T2 (hu) 2016-11-28
LTPA2022509I1 (hu) 2022-06-27
JP2016222701A (ja) 2016-12-28
RU2482878C2 (ru) 2013-05-27
DK2010219T3 (en) 2016-01-11
KR101514913B9 (en) 2022-06-24
EP2679245A2 (en) 2014-01-01

Similar Documents

Publication Publication Date Title
HUS2200028I1 (hu) Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
IL190885A0 (en) Immunogenic compositions and methods of use
IL195237A0 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
ZA201203709B (en) Immunogenic compositions and methods
EP1988918A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
ZA200900347B (en) Preparation of pharmaceutical compositions
EP1986685A4 (en) COMPOSITIONS FOR DISPENSING A VACCINATE AND METHOD FOR THE APPLICATION THEREOF
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2185112A4 (en) STABILIZED THERAPEUTIC COMPOSITIONS AND FORMULATIONS
EP2018182A4 (en) IMMUNOGENIC COMPOSITIONS
EP2001400A4 (en) ORAL FORMULATIONS OF GLYCYL-2-METHYLPROLYL-GLUTAMATE
IL197909A0 (en) Reduction of astringency in polyphenol compositions
EP2076281A4 (en) STABILIZING ALKYLGLYCOSIDIC COMPOSITIONS AND METHODS THEREOF
ZA200810162B (en) Phenylphrine pulsed release formulations and pharmaceutical compositions
ZA200908300B (en) Natural honey-containing compositions and method of preparation
IL192614A0 (en) Antiseptic compositions and methods of using same
ZA200806668B (en) Antiseptic compositions and methods of using same
AU2006906669A0 (en) Methods and Preparation and Uses of Xanthorrhoeaceae Compositions